Who is sponsoring NCT00118924?

NCT00118924 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What condition does NCT00118924 study?

NCT00118924 studies Tick-Borne Encephalitis.

What drugs are being tested in NCT00118924?

Interventions: LGT(TP21)/DEN4, Placebo.

What is the status of NCT00118924?

NCT00118924 is currently COMPLETED.

Last reviewed 2008-01-18 · How we verify

Phase 1 Study of the Safety and Immunogenicity of Tick-Borne Langat/Dengue 4 Chimera (LGT(TP21)/DEN4), a Live Attenuated Vaccine for Tick-Borne Encephalitis

NCT00118924 Phase 1 COMPLETED

Tick-borne encephalitis (TBE) is a viral illness common in the Northern Hemisphere, especially Europe and Asia. TBE infection may lead to central nervous system problems and death. The purpose of this study is to test the safety of and immune response to a TBE vaccine in healthy adults. The vaccine is related to a live attenuated virus developed against dengue virus infection.

Details

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 1
Status	COMPLETED
Enrolment	28
Start date	2005-07
Completion	2007-07

Conditions

Tick-Borne Encephalitis

Interventions

LGT(TP21)/DEN4
Placebo

Primary outcomes

Frequency of vaccine-related adverse effects, graded by intensity and severity through active and passive surveillance — Throughout study
Immunogenicity of vaccine against anti-Langat neutralizing antibody — At Days 0, 28, 42, and 180

Countries

United States